Pamela McLain
Birmingham, ALNPI 1083661961
Payments from drug & device makers
What this record shows
This record is dominated by grants: $553,428 of the $555,846 with a category attached, or 99.6%. AbbVie accounts for 99.6% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $217,480, more than ten times the $992 reported in 2019.
Across 41 payments — averaging $13,557 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$554K
- Novartis$736
- GSK$320
- Regeneron Healthcare Solutions, Inc.$244
- Mallinckrodt Hospital Products Inc.$150
- E.r. Squibb & Sons, L.L.C.$125
- plus $501 from 6 others
What the payments were for
- Grants$553,428100%
- Food & beverage$2,4180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $553,770 |
| Novartis | 8 | $736 |
| GSK | 3 | $320 |
| Regeneron Healthcare Solutions, Inc. | 2 | $244 |
| Mallinckrodt Hospital Products Inc. | 1 | $150 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Radius Health, Inc. | 2 | $121 |
| Amgen | 1 | $108 |
| Johnson & Johnson | 1 | $72 |
| Aurinia Pharma U.S., Inc. | 1 | $61 |
| Fresenius Kabi USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.